Coats病消融治疗中辅助抗VEGF治疗的系统综述与荟萃分析
该系统综述与荟萃分析纳入5项研究(单纯消融136眼、联合抗VEGF 82眼),评估辅助玻璃体腔注射抗VEGF联合标准消融治疗Coats病的疗效与安全性。结果显示联合治疗显著减少达到静息所需的治疗次数(MD 0.47次,95%CI 0.10-0.85,p=0.01),最终BCVA及眼球萎缩等解剖结局无显著差异,牵拉性视网膜脱离风险未见显著升高。
要点
- 辅助抗VEGF可减少Coats病达到静息所需的消融治疗次数。
- 联合治疗与单纯消融在最终BCVA及眼球萎缩等解剖结局上无显著差异。
- 辅助抗VEGF未显著增加牵拉性视网膜脱离风险,但证据等级低。
核心结论
- 辅助抗VEGF治疗可能减少Coats病的总治疗负担,同时获得相似的解剖与功能结局。
- 辅助抗VEGF似乎未显著增加牵拉性视网膜脱离的风险。
- 对需要消融治疗的Coats病患者,审慎使用抗VEGF可能是值得考虑的治疗选择。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和SCOPUS数据库。
- 纳入比较单纯消融治疗与消融联合抗VEGF治疗Coats病的研究,共5项。
- 样本包括单纯消融治疗136眼和联合治疗82眼。
- 提取治疗次数、静息、视力(VA)和牵拉性视网膜脱离(TRD)数据。
- 纳入研究为回顾性设计,总体证据等级评为低。
主要发现
- 辅助抗VEGF显著减少达到静息所需的治疗次数(MD 0.47次,95%CI 0.10-0.85,p=0.01)。
- 两组解剖结局无显著差异,发生眼球萎缩的眼数相似。
- 最终随访BCVA无显著差异(MD=0.20,95%CI -0.20至0.59,p=0.33),异质性不显著(I2=23%,p=0.28)。
- 辅助抗VEGF组未发现牵拉性视网膜脱离风险显著升高(RR 2.64,95%CI 0.34-20.30,p=0.35)。
临床怎么用
- 对需要消融治疗的Coats病患者,可审慎考虑辅助玻璃体腔注射抗VEGF以减少治疗次数。
- 联合治疗未显示最终视力或解剖结局的显著获益,决策需权衡。
- 现有证据等级低,临床应用应结合个体情况并注意监测牵拉性视网膜脱离。
局限性
- 纳入研究均为回顾性设计,总体证据等级评为低。
- 纳入研究数量有限(共5项),样本量较小。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and safety of adjunctive intravitreal anti-vascular endothelial growth factor (VEGF) therapy combined with standard ablative treatment in Coats disease. METHODS: A search of PubMed, Embase, and SCOPUS was conducted to identify studies comparing ablative therapy alone versus ablative therapy with anti-VEGF for Coats disease. Five studies (136 eyes treated with ablation alone and 82 with combination therapy) were included. Data on treatment sessions, quiescence, visual acuity (VA) and tractional retinal detachment (TRD) were extracted. RESULTS: Adjunctive anti-VEGF significantly reduced the treatment sessions required to achieve quiescence (Mean difference [MD] 0.47 sessions, 95% confidence interval [CI] 0.10-0.85, p = 0.01). No significant difference was found in anatomic outcomes with both groups having a similar number of eyes which resulted in phthisis. No significant difference was found in the BCVA at final follow up (MD = 0.20, 95% CI -0.20 to 0.59, p = 0.33) without significant heterogeneity (I2 =23%, p = 0.28). Eyes with adjunctive anti-VEGF were not found to be associated with a significantly higher risk of TRD (RR 2.64, 95% CI 0.34-20.30, p = 0.35). Due to the retrospective design of the included studies, the overall grade of evidence was deemed low. CONCLUSIONS: Adjunctive anti-VEGF therapy may reduce the total treatment burden while achieving similar anatomical and functional outcomes. In addition, there appears to be no significant increase in the risk of TRD. Judicious use of anti-VEGF may be a useful therapy to consider in patients with Coats disease requiring ablative therapy.
引用
- Zhang C, Leung N, Sandhur B, et al. Adjuvant Anti-VEGF Therapy During Ablative Treatment for Coats Disease: A Systematic Review and Meta-Analysis. Retina. 2026. PMID: 42709585. doi:10.1097/IAE.0000000000005008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。